In this snapshot of a cancer patient s immune system, various types of immune cells, marked in different colours, can be seen infiltrating a RAD51-Low ovarian cancer tumour (blue nuclei). Credit: Cancer Science Institute of Singapore, National University of Singapore Read Time:
Epithelial ovarian cancer (EOC) is the most common lethal gynaecological cancer. Ovarian cancer is usually treated with platinum-based chemotherapy; however, a significant number of patients are resistant to such treatments and relapse soon afterwards. To improve their survival, there is a need to first identify which patients may be platinum-resistant, so that newer treatments may be administered early.
Research published in the journal EMBO Molecular Medicine details a novel mechanism that can be used to predict which epithelial ovarian cancer patients (E | Cancer
Researchers from the National University of Singapore have found a way to predict if ovarian cancer patients will be resistant to chemotherapy. By using automated microscopy, they identified a protein that indicates the resistance of ovarian cancer cells to platinum chemotherapy. This breakthrough could improve the survival rate of ovarian cancer patients, as other treatments may be administered early.
Wednesday, 07 Apr 2021 05:59 PM MYT
In pre-clinical tests, the team reported that the chemotherapeutic drug, Topotecan, reduces the morbidity and mortality of SARS-CoV-2 infection. Picture courtesy of Savushkin / Istock.com
Subscribe to our Telegram channel for the latest updates on news you need to know.
SINGAPORE, April 7 An international research collaboration involving researchers from Singapore and the United States has found that a widely available and inexpensive drug used for cancer treatment could potentially be used in the treatment of Covid-19.
In pre-clinical tests, the team reported that the chemotherapeutic drug, Topotecan, reduces the morbidity and mortality of SARS-CoV-2 infection by inhibiting the expression of inflammatory genes in the lungs of laboratory models of Covid-19.
SINGAPORE - A drug used in cancer treatment can treat patients with moderate to severe forms of Covid-19, according to a study by Singapore and US researchers.
They found that Topotecan, which is used in chemotherapy, reduced the severity and death rates of infection by Sars-Cov-2 - the virus causing Covid-19 - by suppressing inflammation in the lungs of laboratory animals.
Patients with moderate to severe forms of Covid-19 suffer from inflammation, a result of an overactive, abnormal immune response. In some patients, an exaggerated immune response - typically occurring in the lungs - can flood the infected area with white blood cells, resulting in severe inflammation, tissue damage and often death.